For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the forecasted revenue size of the disseminated intravascular coagulation (dic) industry by 2029?
The disseminated intravascular coagulation (DIC) market size has grown strongly in recent years. It will grow from $0.46 billion in 2024 to $0.49 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to rise in prevalence of sepsis, increase in trauma cases, growth in cancer incidence, higher healthcare spending, enhanced awareness among healthcare professionals, and rise in adoption of targeted therapies.
The disseminated intravascular coagulation (DIC) market size is expected to see strong growth in the next few years. It will grow to $0.59 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing adoption of targeted therapies, growing focus on early disease detection, rising investments in healthcare infrastructure, expansion of clinical research on coagulopathy treatments, and heightened awareness of rare hematological conditions. Major trends in the forecast period include improved diagnostic assays, adoption of novel anticoagulant therapies, personalized medicine approaches, integration of AI in diagnostics, enhanced patient monitoring technologies, and development of targeted treatments.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21172&type=smp
Which industry-specific innovations are acting as key drivers for the disseminated intravascular coagulation (dic) market?
The increasing prevalence of cancer is expected to drive the growth of the disseminated intravascular coagulation (DIC) market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade and destroy normal tissues. Cancer cases are rising due to factors such as the aging population, lifestyle changes, environmental exposure, infections, and genetic predisposition. Cancer can cause disseminated intravascular coagulation (DIC) by triggering excessive activation of the coagulation cascade through tumor-produced procoagulant substances, leading to widespread clotting and bleeding. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Projections suggest these numbers could increase to 29.9 million new cases and 15.3 million deaths annually by 2040. Therefore, the increasing prevalence of cancer is driving the growth of disseminated intravascular coagulation (DIC) market.
Which segment currently leads the disseminated intravascular coagulation (dic) market in terms of revenue share?
The disseminated intravascular coagulation (DIC) market covered in this report is segmented –
1) By Treatment: Medicines, Transfusions, Surgery, Other Treatments
2) By Diagnosis: Complete Blood Count With Blood Smear Exam, Partial Thromboplastin Time (PTT), Fibrinogen Blood Test, D-dimer, Other Diagnoses
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Medicines: Anticoagulants, Antiplatelet Drugs, Fibrinolytics, Procoagulants, Antithrombin Therapy
2) By Transfusions: Platelet Transfusion, Fresh Frozen Plasma (FFP), Cryoprecipitate Transfusion, Red Blood Cell Transfusion
3) By Surgery: Surgical Removal Of Thrombus, Organ Surgery
4) By Other Treatments: Plasma Exchange, Supportive Care, Steroid Therapy
View The Full Market Report:
What evolving trends are creating new opportunities in the disseminated intravascular coagulation (dic) market?
Major companies operating in the disseminated intravascular coagulation (DIC) market are focusing on advancements in coagulation diagnostic technologies, such as next-generation blood clotting tests, to enhance the accuracy, speed, and ease of diagnosing DIC, allowing for timely intervention and improved patient outcomes. Next-generation blood clotting tests refer to advanced diagnostic tools and methodologies designed to assess blood coagulation more accurately, efficiently, and comprehensively than traditional tests. For instance, in June 2022, LumiraDx Limited, a UK-based healthcare company, expanded its cardiovascular testing portfolio with CE Mark approvals for its NT-proBNP and updated D-Dimer tests. These tests enhance the LumiraDx Platform’s ability to support clinicians in diagnosing heart failure and ruling out venous thromboembolism at the point of care. The advancements aim to improve the early detection and management of cardiovascular and thrombotic conditions, including disseminated intravascular coagulation (DIC).
Who are the top competitors in the global disseminated intravascular coagulation (dic) market?
Major companies operating in the disseminated intravascular coagulation (DIC) market are Nihon Kohden Corporation, Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, Thermo Fisher Scientific Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Danaher Corporation, Eli Lily and Company, Siemens Healthineers, Teva Pharmaceutical Industries Ltd., Mylan N.V., Grifols S.A., Eisai Co. Ltd., Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc.
What regional dynamics are shaping the future of the global disseminated intravascular coagulation (dic) market?
North America was the largest region in the disseminated intravascular coagulation (DIC) market in 2024. The regions covered in the disseminated intravascular coagulation (DIC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Disseminated Intravascular Coagulation (DIC) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21172
Need Customized Data On Disseminated Intravascular Coagulation (DIC) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21172&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
